Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials

Clinical Infectious Diseases

Volumn 64, Issue 1, 2017, Pages 87-91

  Ljungman, Per ^a,b   Boeckh, Michael ^d,e   Hirsch, Hans H ^f   Josephson, Filip ^c   Lundgren, Jens ^g   Nichols, Garrett ^h   Pikis, Andreas ⁱ   Razonable, Raymund R ^j   Miller, Veronica ^k   Griffiths, Paul D ^l  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d Vaccine and Infectious Disease and Clinical Research Division   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Chimerix Inc   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j William J von Liebig Transplant Center   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

Clinical trials; CMV; Organ transplantation; Stem cell transplantation

Indexed keywords

VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA;

ARTICLE; BLOOD ANALYSIS; BRAIN VENTRICULITIS; CLINICAL TRIAL (TOPIC); CYSTITIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; GASTROINTESTINAL INFECTION; GRAFT RECIPIENT; HUMAN; MEDICAL TERMINOLOGY; MYOCARDITIS; NEPHRITIS; NONHUMAN; PANCREATITIS; PRIMARY INFECTION; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; REINFECTION; VIREMIA; VIRUS DETECTION; VIRUS ENCEPHALITIS; VIRUS HEPATITIS; VIRUS PNEUMONIA; VIRUS REACTIVATION; VIRUS REPLICATION; DISEASE MANAGEMENT; PRACTICE GUIDELINE; VIROLOGY;

CYTOMEGALOVIRUS INFECTIONS; DISEASE MANAGEMENT; HUMANS; PRACTICE GUIDELINES AS TOPIC; TRANSPLANT RECIPIENTS;

EID: 85015219866     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw668     Document Type: Article

References (15)

1. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Multidisciplinary approach to understanding cytomegalovirus disease. Paris, Amsterdam: Excerpta Medica International Congress Series, 1993:233-40.
2. Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis 1996; Supplementum 100:59-63.
3. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-7.
4. Miller V. The forum for collaborative HIV research: A model for an integrated and inclusive approach to clinical research and drug development. Clin Pharmacol Ther 2009; 86:332-5.
5. Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Accelerating drug development through collaboration: The Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther 2014; 96:162-5.
6. Fryer J, Heath A, Anderson R, et al. Expert Committee on Biological Standardization: collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO/BS/102138 2010. Geneva, Switzerland: World Health Organization.
7. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA; The City of Hope-Stanford-Syntex CMV Study Group. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-11.
8. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370:1781-9.
9. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-36.
10. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebocontrolled trial. Lancet 2011; 377:1256-63.
11. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haematopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:290-9.
12. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-92.
13. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-37.
14. Hayden RT, Preiksaitis J, Tong Y, et al. Commutability of the First World Health Organization International Standard for human cytomegalovirus. J Clin Microbiol 2015; 53:3325-33.
15. Preiksaitis JK, Hayden RT, Tong Y, et al. Are we there yet? Impact of the 1st International Standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis 2016; 63:583-9.